Amyloid β-Peptide (1-43) (human)
Biological Activity
Human β-amyloid peptide; minor component of neuritic plaques found in brains of patients with Alzheimer's disease.
Technical Data
| M. Wt | 4615.19 |
| Formula | C207H318N56O62S |
| Sequence | DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT |
| Storage | Desiccate at -20°C |
| CAS Number | 134500-80-4 |
| PubChem ID | 90488728 |
| InChI Key | YQWMUHTZOOEROI-ASYIRXGMSA-N |
| Smiles | [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
| Solubility | Soluble to 1 mg/ml in acetic acid |
Product Datasheets
References
References are publications that support the biological activity of the product.
Hilbich et al (1991) Human and rodent sequence analogs of Alzheimer's amyloid βA4 share similar properties and can be solubilized in buffers of pH 7.4. Eur.J.Biochem. 201 61 PMID: 1915378
Jarrett et al (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 4693 PMID: 8490014
Mori et al (1992) Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J.Biol.Chem. 267 17082 PMID: 1512246
If you know of a relevant reference for Amyloid β-Peptide (1-43) (human), please let us know.
View Related Products by Target
Keywords: Amyloid b-peptide (1-43) (human), Amyloid b-peptide (1-43) (human) supplier, Amyloid, β-protein, beta-protein, fragment, β-Amyloid, beta-Amyloid, b-amyloid, Precursor, Protein, APP, Secretase, β-peptide, beta-peptide, (1-43), (human), amyloidbeta, amyloidb, Beta, Peptides, 1938, Tocris Bioscience
Citations for Amyloid β-Peptide (1-43) (human)
Citations are publications that use Tocris products.
Currently there are no citations for Amyloid β-Peptide (1-43) (human). Do you know of a great paper that uses Amyloid β-Peptide (1-43) (human) from Tocris? Please let us know.
Reviews for Amyloid β-Peptide (1-43) (human)
There are currently no reviews for this product. Be the first to review Amyloid β-Peptide (1-43) (human) and earn rewards!
Have you used Amyloid β-Peptide (1-43) (human)?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Neurodegeneration Product Guide
A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:
- Alzheimer's disease
- Parkinson's disease
- Huntington's disease
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
